InvestSMART

SciGen Limited (ASX: SIE) - Announcements

DELISTED - Current share price for SIE : $0.068

ASX company news and announcements for SciGen Limited (SIE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All SciGen Limited (SIE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than SciGen Limited (SIE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for SciGen Limited (SIE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
- SIE and Gulf Pharma enters into Commercialization Agreement 7 Jan 2008 8:31AM $0.092 $0.068 fallen by 26.09%
- SciGen Enters Into Agreement With NasVax 10 Dec 2007 8:28AM $0.092 $0.068 fallen by 26.09%
- Appendix 4C - quarterly 31 Oct 2007 9:12AM $0.094 $0.068 fallen by 27.66%
- SciGen Announces Partnership with Sandoz 11 Sep 2007 8:27AM $0.091 $0.068 fallen by 25.27%
- SciGen Severs Ties With Ferring International 15 Aug 2007 8:26AM $0.085 $0.068 fallen by 20%
- Half Yearly Report and Accounts 15 Aug 2007 8:26AM $0.085 $0.068 fallen by 20%
- Appendix 4C - quarterly 31 Jul 2007 8:26AM $0.081 $0.068 fallen by 16.05%
- SciGen Re-Aquires the Rights to Sci B Vac 28 Jun 2007 8:31AM $0.093 $0.068 fallen by 26.88%
- ScI B Vac Proven to Prevent Recurrence of Hep B 12 Jun 2007 8:24AM $0.090 $0.068 fallen by 24.44%
- Commitments Test Entity - First Quarter Report 30 Apr 2007 11:44AM $0.095 $0.068 fallen by 28.42%
- Preliminary Final Report 28 Feb 2007 9:22AM $0.093 $0.068 fallen by 26.88%
- Commitments Test Entity - Second Quarter Report 31 Jan 2007 8:28AM $0.085 $0.068 fallen by 20%
- Marketing Alliance with Abbott Laboratories 8 Dec 2006 8:29AM $0.084 $0.068 fallen by 19.05%
- Termination of Collaborative Research with Intercell 13 Nov 2006 1:41PM $0.082 $0.068 fallen by 17.07%
- Marketing approval of Hepatitis Vaccine in India 8 Nov 2006 8:30AM $0.082 $0.068 fallen by 17.07%
- Commitments Test Entity - First Quarter Report 31 Oct 2006 8:29AM $0.085 $0.068 fallen by 20%
- Closing of Acquisition of Shreya Biotec 2 Oct 2006 8:34AM n/a $0.068 n/a
- Preliminary Final Report 11 Sep 2006 10:17AM n/a $0.068 n/a
- Commitments Test Entity - Fourth Quarter Report 1 Aug 2006 8:28AM $0.067 $0.068 risen by 1.49%
- Acquisition of GCSF & EPO 21 Jun 2006 8:43AM $0.065 $0.068 risen by 4.62%
- Renegotiated licensing agreement for human insulin 19 Jun 2006 8:29AM $0.062 $0.068 risen by 9.68%
- To acquire Shreya Biotech 5 Jun 2006 9:04AM $0.073 $0.068 fallen by 6.85%
- SciGen Signs Exclusive Worldwide Supply Agreement 2 May 2006 8:30AM $0.090 $0.068 fallen by 24.44%
- JV helps establishment of manufacturing facility 1 May 2006 9:36AM $0.090 $0.068 fallen by 24.44%
- Commitments Test Entity - Third Quarter Report 28 Apr 2006 8:31AM n/a $0.068 n/a

176 - 200 of 239 results

Page 8 of 10

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.